Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(12)
•••
Comment by canadapieton Nov 18, 2019 4:55am
150 Views
Post# 30362982

RE:RE:RE:RE:Littlejohn bought a small amount today

RE:RE:RE:RE:Littlejohn bought a small amount today
Dear Wino,

i am glad you remember the name GLPG, which i did not mention in my last message!

Look up the shareholder structure of both companies and you will see that allmost 80% is in strong hands
(more or less) and only 20% free float. That company has not yet a product on the market but is working 
together with companies like Novartis, Morphosis, Servier, Abbvie and of course GILEAD (who holds 25% and can augment that to 
29,9 % via a special warrant)!!!
Gilead is the company some are mentioning here TH should make a deal with (or are hoping for a  B O ) and is a great play 
in the Nash market. Let that be the market (Nash) where TH is setting
their "hope" on.......!

I am a long term investor on fundamental basis (not a technical analist) and have hold TH for a very 
long time! And like i said before, i don't like to be wrong after i did my torough dd. But here with Th, for now, when you compare the 2 BOD, there is 
a big big big difference between the 2 and their commitment with us, the "little" shareholders.

For now, i did the right thing to sell TH and buy GLPG. Still, I will follow it closely because there is certainly a chance
TH can deliver (again?) in that niche HIV market .But how long is Egrifta on the market?? And only now there can be a breaktrough because of Grinspoon??


I have my doubts (obviously) 

Good luck and happy investing! 


Wino115 - (11/17/2019 1:49:25 PM) 
RE:RE:RE:Littlejohn bought a small amount today
I'm not sure why you keep bringing up Galapagos.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities